Please use this identifier to cite or link to this item: http://10.1.7.192:80/jspui/handle/123456789/9775
Title: Newer Therapeutic Targets for Parkinson Disease
Authors: Gandhi, Samkit S.
Keywords: PPR01019
B. Pharm Project Report
Pharmacology
Parkinson’s diseases
Pathogenesis
Therapeutic targets
α-synuclein
Kinase
Dopamine
PPARγ,
Issue Date: May-2020
Publisher: Institute of Pharmacy, Nirma University, A'bad
Series/Report no.: PPR01019;
Abstract: Parkinson’s disease (PD) occurs mainly at an elderly age. It is the second most occurring neurodegenerative progressive disorder of movement. It is due to aggregation of α-synuclein (a protein normally involved in vesicle recycling) in the form of characteristic Lewy bodies. There are many therapeutic targets available for treatment of PD like α-7 nicotinic receptors, PPARγ and PGC-1α, misfolded α-synuclein and toll-like receptors, the transcription factor Nrf2, mixed lineage kinase(MLK)– c-jun n-terminal kinase (JNK) signaling pathway are the 5 target of therapeutic that has been discussed in this review article.
Description: Guided by Dr. Bhagwati Saxena
URI: http://10.1.7.192:80/jspui/handle/123456789/9775
Appears in Collections:B. Pharm Project Reports

Files in This Item:
File Description SizeFormat 
PPR01019.pdfPPR010192.21 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.